Cancer Innovation最新文献

筛选
英文 中文
Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022 2022年非小细胞肺癌癌症靶向治疗临床研究年度进展
Cancer Innovation Pub Date : 2023-03-01 DOI: 10.1002/cai2.56
Yan Huang, Li Zhang
{"title":"Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022","authors":"Yan Huang,&nbsp;Li Zhang","doi":"10.1002/cai2.56","DOIUrl":"https://doi.org/10.1002/cai2.56","url":null,"abstract":"<p>With the rapid development of lung cancer molecular detection and precision therapy, targeted therapy has covered the entire process of diagnosis and treatment of nonsmall cell lung cancer patients. Overall mortality from lung cancer has decreased significantly over the past 20 years, especially since the introduction of targeted drugs in 2013. In 2022, targeted therapy for lung cancer has developed rapidly. The optimization of treatment modes and the exploration of new target drugs such as antibody-drug conjugates will broaden the selection range of nonsmall cell lung cancer patients with positive driver genes. This article reviews the latest advances in targeted therapy for driver gene-positive lung cancer in 2022.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 1","pages":"25-35"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.56","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50118096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022 2022年晚期癌症和胰腺癌的医学治疗进展
Cancer Innovation Pub Date : 2023-03-01 DOI: 10.1002/cai2.60
Le Zhang, Rui Liu, Ting Deng, Yi Ba
{"title":"Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022","authors":"Le Zhang,&nbsp;Rui Liu,&nbsp;Ting Deng,&nbsp;Yi Ba","doi":"10.1002/cai2.60","DOIUrl":"https://doi.org/10.1002/cai2.60","url":null,"abstract":"<p>This article summarizes the drug therapy progress of advanced hepatocellular carcinoma, biliary tract cancer, and pancreatic cancer in 2022, including chemotherapy, molecular targeted therapy, and immunotherapy, to provide reference information for current clinical treatment and future clinical research, and to better improve prognosis and quality of life in patients with hepatobiliary and pancreatic cancer.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 1","pages":"36-51"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.60","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50118097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Recent advances in immunotherapy for lung cancer 癌症免疫治疗的最新进展
Cancer Innovation Pub Date : 2023-02-24 DOI: 10.1002/cai2.55
Qi Wang, Chunxia Su, Caicun Zhou
{"title":"Recent advances in immunotherapy for lung cancer","authors":"Qi Wang,&nbsp;Chunxia Su,&nbsp;Caicun Zhou","doi":"10.1002/cai2.55","DOIUrl":"https://doi.org/10.1002/cai2.55","url":null,"abstract":"<p>Lung cancer is the malignant tumor with the highest morbidity and mortality in China, and nonsmall cell lung cancer is a common form of lung cancer. After undergoing chemotherapy and molecular targeted therapy, the treatment of lung cancer has now fully entered the era of immunotherapy. Immunotherapy-based treatment has become one of the standard treatments for lung cancer. Immunotherapy has also gradually moved from the back line to the front line, from advanced to early patients. This article focuses on the latest developments in perioperative and advanced lung cancer immunotherapy, discusses the problems and challenges at the current stage, and explores new directions for future development.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 1","pages":"18-24"},"PeriodicalIF":0.0,"publicationDate":"2023-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.55","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50142627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ground glass nodules with scattered or eccentric island-shaped consolidations may have poor outcomes 磨玻璃结节伴有散在或偏心的岛状固结可能预后不佳
Cancer Innovation Pub Date : 2023-02-23 DOI: 10.1002/cai2.48
Ming Li, Junjie Xi, Huan Zhang, Xing Jin, Zhuoyang Fan, Cheng Zhan, Mingxiang Feng, Lijie Tan, Qun Wang
{"title":"Ground glass nodules with scattered or eccentric island-shaped consolidations may have poor outcomes","authors":"Ming Li,&nbsp;Junjie Xi,&nbsp;Huan Zhang,&nbsp;Xing Jin,&nbsp;Zhuoyang Fan,&nbsp;Cheng Zhan,&nbsp;Mingxiang Feng,&nbsp;Lijie Tan,&nbsp;Qun Wang","doi":"10.1002/cai2.48","DOIUrl":"https://doi.org/10.1002/cai2.48","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To explore the effect of scattered or eccentric shaped types of ground glass opacity (GGO) on outcomes of patients with solid-dominant peripheral lung adenocarcinoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We evaluated patients with solid-dominant peripheral lung adenocarcinoma, who underwent radical surgery at Zhongshan Hospital, Fudan University, between January 2013 and December 2015. Morphologically heterogeneous solid-dominant lung adenocarcinoma in imaging findings was based on the last preoperative computed tomography (CT) scans. Endpoints were recurrence-free survival (RFS) and overall survival (OS). Kaplan–Meier analysis and the log-rank test were used to estimate survival differences. Impact factors were assessed by univariable logistic regression analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We retrospectively collected data from 200 patients, including 170 patients with central island-shaped CT imaging, 18 patients with scattered shaped CT imaging, and 12 patients with eccentric shaped CT imaging. Eleven patients experienced recurrence or metastases. Kaplan–Meier survival curves showed significant survival differences between the central island-shaped type and scattered shaped or eccentric shaped type for OS (c-stage IA: 5-year OS: 100% vs. 92.1%; HR = 0.019, <i>p</i> = 0.0025; p-stage IA: 100% vs. 95.2%; HR = 0.146, <i>p</i> = 0.1139) and RFS (c-stage IA: 5-year RFS: 100% vs. 59.7%; HR = 0.001, <i>p</i> &lt; 0.0001; p-stage IA: 100% vs. 64.5%; HR &lt; 0.001, <i>p</i> &lt; 0.0001). Univariable logistic regression analysis showed that scattered and eccentric shaped types were related to poor outcomes (<i>p</i> &lt; 0.012, odds ratio = 18.8).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Relative spatial position of GGO and solid components may affect patient outcomes. Patients with scattered or eccentric shaped GGO may have a poor prognosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 2","pages":"148-158"},"PeriodicalIF":0.0,"publicationDate":"2023-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.48","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50141598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiotherapy, photodynamic therapy, and cryoablation-induced abscopal effect: Challenges and future prospects 放射治疗、光动力治疗和冷冻消融诱导的脓肿效应:挑战和未来前景
Cancer Innovation Pub Date : 2023-02-23 DOI: 10.1002/cai2.53
Sadik Ali Mohammad, Arshadul Hak, Sunil V. Pogu, Aravind K. Rengan
{"title":"Radiotherapy, photodynamic therapy, and cryoablation-induced abscopal effect: Challenges and future prospects","authors":"Sadik Ali Mohammad,&nbsp;Arshadul Hak,&nbsp;Sunil V. Pogu,&nbsp;Aravind K. Rengan","doi":"10.1002/cai2.53","DOIUrl":"https://doi.org/10.1002/cai2.53","url":null,"abstract":"<p>Local therapy modalities such as radiation therapy, photodynamic therapy, photothermal therapy, and cryoablation have been used to treat localized tumors for decades. The discovery of the abscopal effect causes a paradigm shift where local therapy also causes systemic effects and leads to the remission of nonirradiated tumors. The abscopal effect of radiation therapy, alone or in combination with other treatments, has been extensively studied over the last six decades. However, the results are unsatisfactory in producing robust, reproducible, and long-lasting systemic effects. Although immunotherapy and radiation therapy are promising in producing the abscopal effect, the abscopal effect's mechanism is still unclear, owing to various factors such as irradiation type and dose and cancer type. This article reviews the research progress, clinical and preclinical evidence of the abscopal effect by various local therapies alone and in combination with chemotherapy and immunotherapy, case reports, and the current challenges in producing the abscopal effect by various local therapies, focusing on radiotherapy, photodynamic therapy, cryoablation, and the prospects for obtaining a robust, reproducible, and long-lasting abscopal effect.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 5","pages":"323-345"},"PeriodicalIF":0.0,"publicationDate":"2023-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71976428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Ecological view of carcinogenesis: Niche-altering (NC3) mechanisms 致癌作用的生态学观点:生态位改变(NC3)机制
Cancer Innovation Pub Date : 2023-02-21 DOI: 10.1002/cai2.54
Mesut Tez
{"title":"Ecological view of carcinogenesis: Niche-altering (NC3) mechanisms","authors":"Mesut Tez","doi":"10.1002/cai2.54","DOIUrl":"https://doi.org/10.1002/cai2.54","url":null,"abstract":"<p>Over the last 30 years, a new actor in the area of ecology and evolution has emerged: niche construction theory (NCT). The fundamental premise of NCT is that organisms may actively influence evolutionary processes by modifying their circumstances [<span>1</span>]⁠.</p><p>According to Trappes et al., [<span>2</span>] the concept of niche construction should only be applied to species that alter their environment, which they believe to be its intuitive scope. They add two more terms to describe the ways that organisms engage with their surroundings and so influence their niches: when organisms choose their environment, this is known as niche choice, and when they adapt their phenotype to fit their environment, this is known as niche conformance. These three concepts are often referred to as niche-altering mechanisms, or NC<sup>3</sup> mechanisms: niche conformance, niche construction, and niche choice. This is in line with definitions of mechanisms developed in scientific philosophy [<span>2</span>]⁠.</p><p>Cancer was attempted to be explained using NC<sup>3</sup> mechanisms in this essay.</p><p>Carcinogenesis is a three-stage process that includes initiation, progression, and metastasis [<span>3</span>]. Cancer initiation is an example of niche conformance. Phenotypic plasticity, or an organism's ability to develop distinct phenotypes in response to environmental variation, is involved in niche conformance. Unlike phenotypic plasticity, niche conformance also includes how phenotypic adjustment leads to changes in the phenotype-environment match and fitness [<span>2</span>]⁠.</p><p>The constant replacement of old cells with newly formed healthy differentiated cells (progeny) originating from adult stem cells regulates epithelial tissue turnover. Each differentiated cell in an organism expresses a subset of all the genes found in that species' genome. The pattern of gene expression defines a differentiated cell type (hepatocyte, enterocyte, and so on). Adult stem cells are thought to reside in many tissues within a niche formed by a group of cells and an extracellular matrix that provides an optimal environment for the adult stem cell. Furthermore, adult stem cells are resistant to apoptosis, making them more resistant to the damaging effects of environmental stress than their progeny [<span>4, 5</span>]⁠⁠.</p><p>The stress stimulus exposure consists of all current environmental parameters (including the stress stimulus) as well as the organism's phenome (all features of the organism at that moment). The phenomenon of ‘this particular moment’ bears the effects of all previous encounters; the organism has plasticity (the phenomenal repertoire it can demonstrate in response to environmental changes) and abilities due to all previous processes (both from the organism's own life process and from the processes of its ancestors). The organism's plasticity in the face of a stress stimulus is related to its genome, epigenome, phenom, and environment, whi","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 2","pages":"96-98"},"PeriodicalIF":0.0,"publicationDate":"2023-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.54","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50139608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in medical treatment of breast cancer in 2022 2022年癌症医学治疗进展
Cancer Innovation Pub Date : 2023-02-21 DOI: 10.1002/cai2.46
Jingtong Zhai, Yun Wu, Fei Ma, Virginia Kaklamani, Binghe Xu
{"title":"Advances in medical treatment of breast cancer in 2022","authors":"Jingtong Zhai,&nbsp;Yun Wu,&nbsp;Fei Ma,&nbsp;Virginia Kaklamani,&nbsp;Binghe Xu","doi":"10.1002/cai2.46","DOIUrl":"https://doi.org/10.1002/cai2.46","url":null,"abstract":"<p>Breast cancer has replaced lung cancer as the most common malignancy worldwide. The 5-year survival rate of breast cancer has reached 90%. Systemic treatment of breast cancer has developed into a mature system including chemotherapy, targeted therapy, endocrine therapy and immunotherapy. This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 1","pages":"1-17"},"PeriodicalIF":0.0,"publicationDate":"2023-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.46","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50139602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Emerging roles of circular RNAs in the invasion and metastasis of head and neck cancer: Possible functions and mechanisms 环状 RNA 在头颈癌的侵袭和转移中的新作用:可能的功能和机制
Cancer Innovation Pub Date : 2023-02-19 DOI: 10.1002/cai2.50
Shouyi Tang, Luyao Cai, Zhen Wang, Dan Pan, Qing Wang, Yingqiang Shen, Yu Zhou, Qianming Chen
{"title":"Emerging roles of circular RNAs in the invasion and metastasis of head and neck cancer: Possible functions and mechanisms","authors":"Shouyi Tang,&nbsp;Luyao Cai,&nbsp;Zhen Wang,&nbsp;Dan Pan,&nbsp;Qing Wang,&nbsp;Yingqiang Shen,&nbsp;Yu Zhou,&nbsp;Qianming Chen","doi":"10.1002/cai2.50","DOIUrl":"10.1002/cai2.50","url":null,"abstract":"<p>Head and neck cancer (HNC) is the seventh most prevalent malignancy worldwide in 2020. Cancer metastasis is the main cause of poor prognosis in HNC patients. Recently, circular RNAs (circRNAs), initially thought to have no biological function, are attracting increasing attention, and their crucial roles in mediating HNC metastasis are being extensively investigated. Existing studies have shown that circRNAs primarily function through miRNA sponges, transcriptional regulation, interacting with RNA-binding proteins (RBPs) and as translation templates. Among these functions, the function of miRNA sponge is the most prominent. In this review, we summarized the reported circRNAs involved in HNC metastasis, aiming to elucidate the regulatory relationship between circRNAs and HNC metastasis. Furthermore, we summarized the latest advances in the epidemiological information of HNC metastasis and the tumor metastasis theories, the biogenesis, characterization and functional mechanisms of circRNAs, and their potential clinical applications. Although the research on circRNAs is still in its infancy, circRNAs are expected to serve as prognostic markers and effective therapeutic targets to inhibit HNC metastasis and significantly improve the prognosis of HNC patients.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 6","pages":"463-487"},"PeriodicalIF":0.0,"publicationDate":"2023-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.50","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90683775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promoting the application of pediatric radiomics via an integrated medical engineering approach 通过综合医学工程方法促进儿科放射组学的应用
Cancer Innovation Pub Date : 2023-02-19 DOI: 10.1002/cai2.44
Haige Zheng, Fang Wang, Yang Li, Zhicheng Li, Xiaochun Zhang, Xuntao Yin
{"title":"Promoting the application of pediatric radiomics via an integrated medical engineering approach","authors":"Haige Zheng,&nbsp;Fang Wang,&nbsp;Yang Li,&nbsp;Zhicheng Li,&nbsp;Xiaochun Zhang,&nbsp;Xuntao Yin","doi":"10.1002/cai2.44","DOIUrl":"https://doi.org/10.1002/cai2.44","url":null,"abstract":"<p>Radiomics is widely used in adult tumors but has been rarely applied to the field of pediatrics. Promoting the application of radiomics in pediatric diseases, especially in the early diagnosis and stratified treatment of tumors, is of great value to the realization of the WHO 2030 “Global Initiative for Childhood Cancer.” This paper discusses the general characteristics of radiomics, the particularity of its application to pediatric diseases, and the current status and prospects of pediatric radiomics. Radiomics is a data-driven science, and the combination of medicine and engineering plays a decisive role in improving data quality, data diversity, and sample size. Compared with adult radiomics, pediatric radiomics is significantly different in data type, disease spectrum, disease staging, and progression. Some progress has been made in the identification, classification, stratification, survival prediction, and prognosis of tumor diseases. In the future, big data applications from multiple centers and cross-talent training should be strengthened to improve the benefits for clinical workers and children.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 4","pages":"302-311"},"PeriodicalIF":0.0,"publicationDate":"2023-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.44","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50152305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives 辅助和新辅助免疫疗法治疗可切除的癌症(NSCLC)的现状和前景
Cancer Innovation Pub Date : 2023-02-19 DOI: 10.1002/cai2.49
Ziyi Xu, Zihua Zou, Xuezhi Hao, Puyuan Xing, Junling Li
{"title":"Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives","authors":"Ziyi Xu,&nbsp;Zihua Zou,&nbsp;Xuezhi Hao,&nbsp;Puyuan Xing,&nbsp;Junling Li","doi":"10.1002/cai2.49","DOIUrl":"https://doi.org/10.1002/cai2.49","url":null,"abstract":"<p>Surgery followed by adjuvant chemotherapy is the standard of care for selected patients with early-stage or locally advanced non-small cell lung cancer (NSCLC). However, many of these patients still experience postoperative recurrence at 5 years. At present, peri-operative treatment methods are emerging to prevent early relapse, such as targeted therapy and immunotherapy. Investigation on predictive biomarkers of responses to adjuvant and neoadjuvant therapies is also continuously ongoing. Immunotherapy represented by immune checkpoint inhibitors (ICIs), either by monotherapy or in combination with chemotherapy, has shown benefit in promoting pathological responses and prolonging survival for patients with NSCLC without oncogenic mutations. Exploratory studies have also provided evidence regarding the selection of patients who benefit from ICI-based perioperative treatment. This review focuses on the existing data of current clinical trials of adjuvant and neoadjuvant strategies with ICIs in resectable NSCLC, the exploration of predictive biomarkers, and the perspectives and urgent challenges in the future.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 1","pages":"65-78"},"PeriodicalIF":0.0,"publicationDate":"2023-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.49","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50152304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信